HKD 0.2
(4.81%)
Year | Revenue | Revenue Growth |
---|---|---|
2023 | 39.25 Million CNY | 0.0% |
2022 | - CNY | 0.0% |
2021 | - CNY | 0.0% |
2020 | - CNY | 0.0% |
2019 | - CNY | 0.0% |
Year | Revenue | Revenue Growth |
---|---|---|
2024 Q1 | -5.05 Million CNY | -125.9% |
2024 Q2 | -5.05 Million CNY | 0.0% |
2023 FY | 39.25 Million CNY | 0.0% |
2023 Q2 | 128.5 Thousand CNY | 0.0% |
2023 Q1 | 128.5 Thousand CNY | 0.0% |
2023 Q4 | 19.49 Million CNY | 0.0% |
2023 Q3 | 19.49 Million CNY | 15074.32% |
2022 Q2 | 7.44 Million CNY | 0.0% |
2022 Q1 | 7.44 Million CNY | 0.0% |
2022 FY | - CNY | 0.0% |
2022 Q4 | - CNY | 0.0% |
2022 Q3 | - CNY | -100.0% |
2021 Q2 | - CNY | 0.0% |
2021 FY | - CNY | 0.0% |
2021 Q4 | - CNY | 0.0% |
2021 Q3 | - CNY | 0.0% |
2021 Q1 | - CNY | 0.0% |
2020 FY | - CNY | 0.0% |
2019 FY | - CNY | 0.0% |
Name | Revenue | Revenue Difference |
---|---|---|
Uni-Bio Science Group Limited | 484.71 Million HKD | 91.901% |
CK Life Sciences Int'l., (Holdings) Inc. | 5.32 Billion HKD | 99.263% |